Insomnia Clinical Trials 2026: Recruiting Sleep Disorder Studies

Insomnia disorder — difficulty falling asleep, staying asleep, or waking too early, with daytime consequences — affects an estimated 10–15% of adults chronically and up to 30% transiently. Yet the pharmacological treatment landscape has barely shifted in decades: benzodiazepine receptor agonists with their dependency and rebound risk, or newer orexin antagonists with a cleaner profile but a significant price tag and individual response variability. The 2026 research pipeline is exploring a third wave: digital therapeutics validated by randomized trial, novel receptor targets beyond GABA and orexin, and precision sleep medicine matching treatment to underlying insomnia subtype. For chronic insomnia patients who have been bounced between sleeping pills and wake-up advice, these trials represent something more substantive.

Orexin Receptor Antagonists (DORAs)

Orexin (hypocretin) is the wakefulness-promoting neurotransmitter that keeps you alert. Blocking it — rather than broadly sedating the brain like benzodiazepines — produces sleep without the dependency and next-morning cognitive impairment profile. Suvorexant (Belsomra) and lemborexant (Dayvigo) are approved DORAs; the 2026 pipeline is testing:

• Seltorexant — a selective orexin-2 receptor antagonist (as opposed to dual OX1/OX2 blockade), potentially with a more targeted sleep-maintenance profile
• Lower-dose lemborexant formulations for next-day driving impairment reduction
• DORA combination with low-dose melatonin for sleep-onset plus sleep-maintenance insomnia
• DORAs in special populations: older adults, patients with comorbid depression, and shift workers

These trials are typically 4–12 weeks, fully outpatient, with in-home actigraphy monitoring replacing overnight sleep lab visits in many protocols.

Digital CBT-I as a Prescription Therapeutic

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line recommended treatment for chronic insomnia — more effective than sleep medication in head-to-head trials, with no dependency risk. The problem is access: there are an estimated 1 CBT-I-trained therapist for every 2,000 insomnia patients. Digital CBT-I programs delivered via app or web platform are being validated in randomized controlled trials as FDA-regulated prescription digital therapeutics (PDTs).

Sleepio (Big Health) received FDA authorization in 2023. Trials in 2026 are testing:

• Digital CBT-I head-to-head against lemborexant in a 12-week RCT
• CBT-I plus DORA combination vs. each alone for severe chronic insomnia
• AI-personalized sleep restriction protocols adjusted weekly based on actigraphy data
• CBT-I in oncology patients with cancer-related insomnia

Digital trials are often fully remote: app download, wrist actigraphy device by mail, and video check-ins. No clinic visits required in many protocols.

Melatonin and Circadian-Phase Insomnia

Not all insomnia is the same subtype. Delayed sleep phase disorder (DSPD) — where the circadian clock is shifted 2–4 hours late — causes people to be genuinely unable to fall asleep at "normal" bedtimes, often misdiagnosed as insomnia disorder. Trials in 2026 investigate:

• Low-dose melatonin timing protocols: 0.5mg administered 5–6 hours before desired sleep onset to phase-advance the circadian clock
• Tasimelteon (MT1/MT2 agonist, approved for Non-24 disorder) in DSPD and insomnia with circadian component
• Light therapy + melatonin combined with actigraphy-guided timing

Insomnia in Comorbid Conditions

Many insomnia trials recruit specifically patients with a comorbid condition, because insomnia in that context is both more prevalent and harder to treat:

• Insomnia + depression: seltorexant (which has shown antidepressant signal in addition to sleep benefit) trials target this overlap population
• Insomnia + chronic pain: bidirectional relationship — sleep deprivation worsens pain sensitivity; pain disrupts sleep. Trials testing sleep treatment's effect on pain outcomes
• Menopausal insomnia: trials of non-hormonal options (fezolinetant for hot flash-driven sleep disruption; CBT-I adapted for vasomotor symptoms)
• Post-COVID insomnia: structured sleep intervention trials in long-COVID populations where insomnia prevalence exceeds 40%

Who Can Join an Insomnia Trial?

Typical inclusion criteria for chronic insomnia trials:

• Difficulty falling asleep or staying asleep ≥3 nights per week for ≥3 months
• Daytime consequences: fatigue, mood disturbance, concentration difficulty, or functional impairment
• Age 18–75 (some trials extend to 80+)
• Pittsburgh Sleep Quality Index (PSQI) score above threshold (usually ≥5)

Common exclusion criteria include: untreated sleep apnea (OSA must typically be diagnosed and on stable CPAP before joining insomnia trials), severe psychiatric illness, current use of benzodiazepines or Z-drugs (a washout period is required for most trials), and shift work with rotating night schedules.

What Participation Involves

Insomnia trials are among the most patient-friendly in clinical research:

• Duration: typically 4–16 weeks of active treatment, with optional 6–12 month follow-up
• Monitoring: wrist actigraphy device (worn like a watch), sleep diary, weekly online questionnaires
• In-person visits: 1–4 clinic visits for screening and assessment; many protocols are then fully remote
• No overnight stays: unlike sleep apnea studies, insomnia trials rarely require polysomnography in a sleep lab
• Compensation: typically $150–$400 total for participant time

Related Insights